Presbyopia is a common variant of farsightedness affecting over 128 million people in the US, including the majority of ...

Vizz is the first and only aceclidine-based eye drop to improve near vision in adults with presbyopia. Vizz contracts the ...

The first aceclidine-based eye drop to improve near vision in adults with presbyopia, which affects more than 100 million ...

The FDA has approved VIZZ eye drops (LENZ Therapeutics, Inc.) for the treatment of presbyopia, the gradual loss of near ...

Known as Vizz, the once-daily eye drops treat age-related blurry near vision — also known as presbyopia — for up to 10 hours at a time.

Our data shows VIZZ (aceclidine 1.44%) received FDA approval in July 2025, positioning the once-daily, preservative-free ...

LENZ Therapeutics ( (LENZ) ) has shared an announcement. On July 31, 2025, LENZ Therapeutics announced the FDA approval of VIZZ, an aceclidine-based eye drop for treating presbyopia in adults, ...

Aceclidine is a cholinergic muscarinic agonist that causes contraction of the iris sphincter muscle, thereby creating a pinhole effect that extends focus depth to improve vision in presbyopia.

The US Food and Drug Administration has approved Vizz eye drops. These drops improve near vision for adults over 40. Lenz ...

Lenz Therapeutics has earned the FDA’s go-ahead for its aceclidine eye drop to crack the large presbyopia market, where past ...

Vizz (Lenz Therapeutics) is the first and only aceclidine-based eye drop for presbyopia and is also the first daily solution ...

The FDA approved aceclidine 1.44% ophthalmic solution (Vizz) for adults with presbyopia, or age-related blurred near vision, ...